Prospective sampling in intravenously treated oncology patients: Monoclonal AntiBodies

Prospective sampling in intravenously treated oncology patients: Monoclonal AntiBodies - MULTOMAB

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53070

Enrollment

2750

Registered

2016-02-18

Start date

2016-04-05

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer malignancy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age >=18 years • Able to understand the written information and able to give informed consent • Planned treatment with (intravenous) monoclonal antibodies

Exclusion criteria

Exclusion criteria: • Unable to draw blood for study purposes

Design outcomes

Secondary

Measure	Time frame
immunogenicity, characterization of immune cells, tumor response (circulating tumor DNA and germline DNA), hemostatic markers, characteristics of the gut microbiome, immunosenescence	—

Primary

Measure	Time frame
trough level of monoclonal antibodies	—

Countries

Netherlands

Outcome results